|

Tafasitamab Clinical Trials

11 actively recruiting trials across 8 locations

▼ -2 trials since May 2026

Also known as: 1422527-84-1, Anti-(Human Cd19 Antigen) (Human-mus musculus Monoclonal MOR00208 Heavy Chain), Dimer, Disulfide with Human-mus musculus Monoclonal MOR00208 .Kappa.-chain,, Immunoglobulin +7 more

Pipeline

Phase 1: 1Phase 2: 7Phase 1/2: 3

Top Sponsors

  • M.D. Anderson Cancer Center2
  • University of Washington1
  • University of Cologne1
  • SWOG Cancer Research Network1
  • OHSU Knight Cancer Institute1

Indications

  • Cancer10
  • Grade 3b Follicular Lymphoma2
  • High-grade B-cell Lymphoma2
  • Systemic Sclerosis1
  • Lupus Nephritis1

Other2 trials

Extension Study to Provide Continued Treatment for Patients With Hematologic Malignancies Previously Enrolled in Studies With Tafasitamab
Phase 2
Methotrexate, Tafasitamab, Lenalidomide and Rituximab in Patients With PCNSL
Phase 2

Houston, Texas2 trials

A Phase II Trial of Mosunetuzumab, Polatuzumab, Tafasitamab, and Lenalidomide in Patients With Relapsed B-cell NHL

M D Anderson Cancer Center

Phase 2
Phase I/II Study of AD-PluReceptor Plus Tafasitamab-cxix and Lymphodepleting Chemotherapy in Patients With Autoimmune Disorders

MD Anderson Cancer Center

Phase 1/2

Tucson, Arizona1 trial

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

Banner University Medical Center - Tucson

Phase 2

Miami, Florida1 trial

Zanubrutinib and Tafasitamab in Mantle Cell Lymphoma

University of Miami

Phase 1/2

Minneapolis, Minnesota1 trial

HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL

Masonic Cancer Center

Phase 2

Rochester, Minnesota1 trial

Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma

Mayo Clinic in Rochester

Phase 2

Columbus, Ohio1 trial

Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma

Ohio State University Comprehensive Cancer Center

Phase 2

Portland, Oregon1 trial

Tafasitamab, Acalabrutinib, and Obinutuzumab for the Treatment of Previously Untreated Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

OHSU Knight Cancer Institute

Phase 1

Seattle, Washington1 trial

Tafasitamab, Retifanlimab, and Rituximab in Combination With Standard Therapy for the Treatment of Diffuse Large B-cell Lymphoma

Fred Hutch/University of Washington Cancer Consortium

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.